bDMARDs Quick Reference Guide
Severe chronic plaque psoriasis
None
Pre-filled syringe 75mg/0.83mL
Instructions for patient self-administration are available from https://www.medsinfo.com.au/media/veisky75
A QR code that can be scanned for more information is also available on the packaging.
Store at 2-8oC (refrigerate do not freeze).
Keep pre-filled syringes in the outer carton until time of use to protect from light.
For a more comfortable injection, patients may remove the carton from the refrigerator before injecting and allow to reach room temperature (15-30 minutes) out of direct sunlight without removing the pre-filled syringes from the outer carton.
150mg (2 x 75mg injections) at week 0 and week 4, then every 12 weeks thereafter.
The two injections should be administered at least 3cm apart.
Risankizumab has the potential to reactivate latent TB (begin TB treatment before starting).
Patients with suspected latent or active TB should be treated in consultation with an Infectious Diseases physician.
Risankizumab may increase the risk of infection. Treatment should not be initiated in patients with clinically significant active infection until the infection resolves or is adequately treated.
Live vaccines should not be given concurrently with risankizumab.
Pharmaceutical benefits Scheme (PBS) listing. Available from https://www.pbs.gov.au/medicine/item/11827L-11858D [accessed 8/10/21]
Product information. Available from https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2019-PI-01702-1 [accessed 11/5/21]
Australian Medicines Handbook 2020 (online). Adelaide: Australian Medicines Handbook Pty Ltd; 2020 July. Available from: https://amhonline.amh.net.au/